Pfizer wins Canadian OK for hemophilia treatment, its first gene therapy

Dive Brief: Canada’s health regulators have approved Pfizer’s gene therapy for hemophilia B, the company said Wednesday, making it the first time the drugmaker has received regulatory clearance for such a genetic medicine. The gene therapy, which Pfizer licensed nine years ago from Spark Therapeutics, will compete with CSL’s Hemgenix, a similar treatment that gained…

Read More